1 Pathogenesis of Crohn's disease

https://doi.org/10.1016/S0950-3528(98)90083-5Get rights and content

Abstract

In the absence of a single initiating aetiological factor, most workers envisage Crohn's disease as the manifestation of poorly regulated immune and inflammatory processes within the gut wall. Initially these responses may arise as a response to common antigens associated with the gut—bacterial products being amongst the most obvious candidates. In genetically predisposed individuals there is overexpression both of local immune response mechanisms in the gut wall (T-cells, B-cells and macrophages) and of systemic inflammatory cells (predominantly polymorphonuclear leukocytes), which are attracted into the inflamed gut through activation of adhesion molecules on the vascular endothelium. As a consequence a large number of pro-inflammatory processes are expressed in the gut wall, inadequately checked by the normal counter-inflammatory processes that should serve to limit inflammation. Defining the relative importance of the individual processes, and identifying critical steps that could be inhibited or enhanced for therapeutic purposes, is a major challenge of Crohn's disease research.

References (75)

  • R Kuhn et al.

    IL-10 deficient mice develop chronic enteroclitis

    Cell

    (1993)
  • K Lauritsen et al.

    In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis

    Gastroenterology

    (1988)
  • F Procaccino et al.

    Protective effect of epidermal growth factor in an experimental model of colitis in rats

    Gastroenterology

    (1994)
  • LI Roman et al.

    Expanded CD4+CD45RO+ phenotype and defective proliferative response in T lymphocytes from patients with Crohn's disease

    Gastroenterology

    (1996)
  • B Sadlack et al.

    Ulcerative colitis-like disease in mice with a disrupted intefieukin-2 gene

    Cell

    (1993)
  • SH Saverymuttu et al.

    Indium-111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease

  • GW Stamp et al.

    Lysozyme gene expression in inflammatory bowel disease

    Gastroenterology

    (1992)
  • W Strober et al.

    Reciprocal IFN-gamma and IGF-beta responses regulate the occurrence of mucosal inflammation

    Immunology Today

    (1997)
  • AJ Wakefield et al.

    Granulomatous vasculitis in Crohn's disease

    Gastroenterology

    (1991)
  • AJ Wakefield et al.

    Crohn's disease: pathogenesis and persistent measles virus infection

    Gastroenterology

    (1995)
  • KR Youngman et al.

    Localisation of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells

    Gastroenterology

    (1993)
  • EO Adeyemi et al.

    Lactoferrin: a correlate of disease activity in inflammatory bowel disease

    European Journal of Gastroenterology and Hepatology

    (1991)
  • EO Adeyemi et al.

    Faecal elastase reflects disease activity in active ulcerative colitis

    Scandinavian Journal of Gastroenterology

    (1992)
  • EO Adeyemi et al.

    Circulating human leucocyte elastase in patients with inflammatory bowel disease

    Gut

    (1985)
  • A Belluzzi et al.

    Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease

    New England Journal of Medicine

    (1996)
  • G Bouma et al.

    Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumour necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls

    Scandinavian Journal of Gastroenterology

    (1995)
  • M Brachle et al.

    Keratinocyte growth factor is highly over-expressed in inflammatory bowel disease

    American Journal of Pathology

    (1996)
  • P Brandtzaeg

    Immunopathology of Crohn's disease

    Annals of Gastroenterology and Hepatology, Paris

    (1985)
  • C Cocito et al.

    Paratuberculosis

    Clinical Microbiological Review

    (1994)
  • CE Collins et al.

    Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease

    Alimentary Pharmacology and Therapeutics

    (1996)
  • F Cominelli et al.

    Interleukin-1 (IL-I) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis

    Journal of Clinical Investigation

    (1990)
  • F Cominelli et al.

    Specific mucosal imbalance of IL-1 and IL-1 receptor antagonist (IL-1ra) in IBD: a potential mechanism of chronic inflammation

    Gastroenterology

    (1994)
  • R Duchmann et al.

    Bacteria-specific T cell clones are selective in their reactivity towards different enterobacteria or H. pylori and increased in inflammatory bowel disease

    Scandinavian Journal of Immunology

    (1996)
  • RH Duerr et al.

    Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis

    Gastroenterology

    (1991)
  • HM van Dulleman et al.

    Treatment of Crohn's disease with anti- tumour necrosis factor chimeric monoclonal antibody (cA2)

    Gastroenterology

    (1995)
  • J Emerit et al.

    Phase II trial of copper zinc superoxide dismutase (CuZn SOD) in the treatment of Crohn's disease

    Free Radical Research Communications

    (1991)
  • S Fu et al.

    Inducible nitric oxide synthetase (iNOS) and cyclooxygenase (COX-2) expression in ulcerative colitis and Crohn's disease

    Gastroenterology

    (1996)
  • Cited by (20)

    • Cytokines and therapy in COPD: A promising combination?

      2002, Chest
      Citation Excerpt :

      Studies in vivo in mice and humans have revealed that TNF-α is involved in the recruitment of macrophages to sites of inflammation. Thus, in chronic colitis (Crohn's disease) and rheumatoid arthritis, diseases characterized by the presence of macrophages, T cells, and neutrophils,62,63 therapy with neutralizing antibodies directed against TNF-α reduces the inflammation, whereas clinically the patients improved, showing reduced symptoms and an improved quality of life.64,65,66,67,68 In addition, in Crohn's disease, > 30% of the fistulae closed.67

    • Detection of Mycobacterium avium subspecies paratuberculosis in Crohn's diseased tissues by in situ hybridization

      2001, American Journal of Gastroenterology
      Citation Excerpt :

      Although controversial, further support of the mycobacterial etiology in CD disease are: 1) the recent emergence of cell wall-deficient (CWD) forms of M. paratuberculosis in cultures from tissue specimens and milk of a portion of the patients with CD (7–13), 2) the high frequency in detecting M. paratuberculosis DNA in CD tissues (14–18), 3) the successful therapy of CD patients with antimycobacterial treatment containing macrolide antibiotics (19–21), and 4) the specific seroreactivity of the majority of CD patient serum samples specifically against M. paratuberculosis antigens (22–24). The variation of disease severity, relapses, and remissions, and response to treatment between individual patients, however, makes these results inconsistent among all investigators and creates controversy about an etiology of this disease (25–27). Hence, it is tempting to believe of CD as a group of disorders, of different etiologies, but with similar presentation and that one of these disorders is triggered or caused by M. paratuberculosis, specifically its CWD form.

    • Established and emerging biological activity markers of inflammatory bowel disease

      2000, American Journal of Gastroenterology
      Citation Excerpt :

      In CD, the presence of abscesses may lead to elevated PMN counts, while complicating lymphangiectasia results in lymphocyte loss through the intestinal wall, and thus a reduced number of circulating T cells (15). In some UC patients a distinct leukocytosis occurs, which, at the tissue level, may be associated with the healing phase (16). However, in general, this marker is not useful for assessment of IBD activity in clinical practice.

    • Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: Results of the European study on glycogen storage disease type I

      2000, Journal of Pediatrics
      Citation Excerpt :

      The IBD in GSD-Ib resembles Crohn's disease and may involve the entire gastrointestinal tract. In the absence of a single etiologic factor, Crohn's disease can be regarded as a manifestation of poorly regulated immune and inflammatory processes within the gut wall.28 In most cases of Crohn's disease, neutrophils probably contribute to the tissue damage.29

    • New emerging and re-emerging bacterial foodborne pathogens

      2012, Kafkas Universitesi Veteriner Fakultesi Dergisi
    View all citing articles on Scopus
    View full text